Indication
Neoplasm
19 clinical trials
24 products
5 drugs
Clinical trial
A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors With an Expansion Cohort in HIV Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin LymphomaStatus: Recruiting, Estimated PCD: 2024-07-01
Drug
T-VECClinical trial
A Phase II Clinical Trial to Investigate ARID1A Mutation and CXCL13 Expression in the Pre-Treatment Tumor Samples as a Combinatorial Predictive Biomarker for Immune Checkpoint Therapy in Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2027-05-31
Product
NivolumabClinical trial
A Phase I Trial of Ipilimumab (Immunotherapy) and Imatinib Mesylate (c-Kit Inhibitor) in Patients With Advanced MalignanciesStatus: Completed, Estimated PCD: 2022-12-13
Product
ImatinibProduct
IpilimumabClinical trial
A Phase I Trial of ABT-263 (Navitoclax), a Bcl-2 Inhibitor, and Sorafenib (Nexavar) in Patients With Relapsed or Refractory Solid Organ TumorsStatus: Active (not recruiting), Estimated PCD: 2022-11-30
Product
NavitoclaxProduct
SorafenibClinical trial
Phase 1/2 Study of Navitoclax Plus Vistusertib in Patients With Relapsed Small Cell Lung Cancer (SCLC) and Other Solid TumorsStatus: Terminated, Estimated PCD: 2021-07-28
Product
VistusertibClinical trial
Phase II Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare TumorsStatus: Active (not recruiting), Estimated PCD: 2025-12-31
Product
PembrolizumabClinical trial
Phase I Study of MLN0128 (TAK-228) (NSC# 768435) in Combination With Ziv-Aflibercept (NSC# 724770) in Patients With Advanced CancersStatus: Completed, Estimated PCD: 2021-06-29
Product
SapanisertibProduct
Ziv-AfliberceptClinical trial
A Phase I Trial of Vemurafenib in Combination With Cetuximab and Irinotecan in Patients With BRAF V600 Mutant Advanced Solid MalignanciesStatus: Active (not recruiting), Estimated PCD: 2026-03-31
Product
CetuximabProduct
IrinotecanProduct
VemurafenibClinical trial
A Phase I Study of AZD8186 in Combination With Docetaxel in Patients With PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to DocetaxelStatus: Active (not recruiting), Estimated PCD: 2022-07-25
Drug
DocetaxelProduct
AZD8186Clinical trial
A Phase I Study to Evaluate the Safety of Trigriluzole (FC-4157/BHV-4157) in Combination With PD-1 Blocking AntibodiesStatus: Completed, Estimated PCD: 2022-10-20
Product
Enzyme InhibitorDrug
mFOLFOX6Clinical trial
Non Invasive Cancer Test (NICT): a Proof of Principle Study.Status: Recruiting, Estimated PCD: 2024-03-01
Product
Isolation of tumor DNAClinical trial
A Phase 1/2 Trial of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients With Solid Tumors (Phase 1) and Relapsed Ovarian Cancer or Primary Peritoneal Cancer (Phase 2) After Prior Platinum Containing First-Line ChemotherapyStatus: Active (not recruiting), Estimated PCD: 2019-01-13
Product
TopotecanProduct
VeliparibClinical trial
A Phase I Study of GNX102 in Patients With Advanced Solid TumorsStatus: Terminated, Estimated PCD: 2023-07-26
Product
GNX102Clinical trial
A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664) Plus Intravenous Irinotecan (CPT-11, NSC#616348) Administered in Patients With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2023-06-30
Clinical trial
A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia, and Select Solid Tumors and Varying Degrees of Liver DysfunctionStatus: Active (not recruiting), Estimated PCD: 2018-11-29
Product
RomidepsinClinical trial
A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other IndicationsStatus: Active (not recruiting), Estimated PCD: 2026-03-31
Drug
AtezolizumabDrug
cetuximabProduct
TemsirolimusProduct
Valproic AcidClinical trial
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic DysfunctionStatus: Active (not recruiting), Estimated PCD: 2023-08-04
Product
TrametinibClinical trial
A Phase 1 Trial of the Combination of the Heat Shock Protein-90 (HSP90) Inhibitor Onalespib (AT13387) and the Cyclin-Dependent Kinase (CDK) Inhibitor AT7519M in Patients With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2020-08-15
Product
AT7519Product
OnalespibClinical trial
Phase I/Ib Study of Nivolumab and Veliparib in Patients With Advanced Solid Tumors and Lymphoma With and Without Alterations in Selected DNA Repair GenesStatus: Completed, Estimated PCD: 2018-03-11